Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) ROCE % : -13.97% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biocytogen Pharmaceuticals (Beijing) Co's annualized ROCE % for the quarter that ended in Dec. 2023 was -13.97%.

Biocytogen Pharmaceuticals (Beijing) Co ROCE % Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co ROCE % Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-22.73

-26.71

-25.78

-13.64

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial			-29.84	-28.43	-29.89	-13.25	-13.97

Biocytogen Pharmaceuticals (Beijing) Co ROCE % Calculation

Biocytogen Pharmaceuticals (Beijing) Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-306.599	/	( ( (3126.614 - 676.78)	+	(2679.111 - 631.784) )	/ 2 )
	=	-306.599	/	( (2449.834	+	2047.327)	/ 2 )
	=	-306.599	/	2248.5805
	=	-13.64 %

Biocytogen Pharmaceuticals (Beijing) Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-300.98	/	( ( (2972.664 - 710.477)	+	(2679.111 - 631.784) )	/ 2 )
	=	-300.98	/	( ( 2262.187	+	2047.327 )	/ 2 )
	=	-300.98	/	2154.757
	=	-13.97 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biocytogen Pharmaceuticals (Beijing) Co ROCE % Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.

Executives

Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you
Cmb International Investment Management Limited	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Headlines

No Headlines